Monday, July 21, 2014

Amgen Foundation Grants $25K to a Colorado STEM Education program

Colorado BioScience Association is honored to announce the Amgen Foundation’s grant of $25,000 to the Colorado BioScience Institute in support of the Research Experience for Teachers (RET) program in Colorado’s science classrooms.

The RET program is an intensive, 4 week, hands-on program for 7th-12th grade teachers. This inaugural year, four teachers were selected to participate. The RET program places teachers in local life science companies to provide them with hands-on lab experience to bridge real-world skills to back the classroom.

The goal is to help build long-term collaborative partnerships between, industry scientists, and the local university research community by involving the teachers in real bioscience research and helping them translate their research experiences and new knowledge into classroom activities.

2014 RET Hosting Companies:

Biodesix, Inc., Aurora, Boulder Molecular diagnostics advancing personalized medicine www.biodesix.com

iC42 Clinical Research & Development, Aurora Contract research services for integrated solutions to systems biology www.bioanalytics.us

Sharklet Technologies, Inc., Aurora Engineers surface technologies (Sharklet™) that controls the growth of dangerous bacteria www.sharklet.com 

Surefire Medical Inc., Westminster Developing a novel infusion system for the interventional radiology market www.surefiremedical.com

The Amgen Foundation seeks to advance science education, improve patient access to quality care, and strengthen the communities where Amgen staff members live and work. To date, the Foundation has donated more than $200 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally. For more information, visit http://www.amgen.com/citizenship/overview.html and follow us on http://www.twitter.com/AmgenFoundation.

Link to the Business Wire

Link to the PitchEngine Social Media Release

No comments:

Post a Comment